Latigo Biotherapeutics, Inc.
Research Latigo Biotherapeutics, Inc. (LTGO) on Bullrun: market cap USD 928.19M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLTGO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 928.19M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 25.80M
- Free cash flow-USD 21.39M
Valuation Snapshot
latest market cap is USD 928.19M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 109.17M | -USD 97.69M | n/a | -2.48 | USD 69.44M | USD 690.00K | -USD 231.67M |
| FY2024 | USD 0 | -USD 61.18M | -USD 51.03M | n/a | -1.39 | USD 17.92M | USD 851.00K | -USD 129.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | USD 928.19M | n/a | n/a | n/a |
About Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Latigo Biotherapeutics, Inc.'s market cap?
Latigo Biotherapeutics, Inc.'s market capitalization is USD 928.19M.
What does Latigo Biotherapeutics, Inc. do?
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc.